GHIA, PAOLO PROSPERO
 Distribuzione geografica
Continente #
NA - Nord America 77
EU - Europa 56
AS - Asia 3
AF - Africa 1
Totale 137
Nazione #
US - Stati Uniti d'America 76
IT - Italia 30
FR - Francia 15
DE - Germania 6
NL - Olanda 3
IN - India 2
CN - Cina 1
IE - Irlanda 1
MA - Marocco 1
MX - Messico 1
UA - Ucraina 1
Totale 137
Città #
Ashburn 68
Milan 9
Bergamo 5
Frankfurt am Main 5
Rome 4
Paris 3
Vicenza 3
Amsterdam 2
Coimbatore 2
Olbia 2
Belluno 1
Dublin 1
Gualtieri 1
Khemisset 1
Los Angeles 1
Mexico City 1
Monza 1
Savona 1
Seattle 1
Shanghai 1
Turin 1
Totale 114
Nome #
T cell receptor gene repertoire profiles in subgroups of patients with chronic lymphocytic leukemia bearing distinct genomic aberrations, file ed6e5641-a1b9-4018-a457-29b157c7ef2c 69
Cytogenetics in Chronic Lymphocytic Leukemia: ERIC Perspectives and Recommendations, file a3ec1994-714d-49fb-984a-b41d5ea04c37 16
PYK2 is overexpressed in chronic lymphocytic leukaemia: A potential new therapeutic target, file 353c1a00-1f4f-497a-8e22-5fe56f95d30c 10
Is good clinical practice becoming poor clinical care?, file 85da6ceb-2f2b-440b-a506-31d675054265 8
Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia, file a19c8999-4e59-4273-b603-b533eb2485cd 8
BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib, file eaa29f33-98ce-4354-a143-8270e1c154d3 8
B-cell receptor pathway mutations are infrequent in patients with chronic lymphocytic leukemia on continuous ibrutinib therapy, file aa76aaba-2b80-4078-8a59-dac3acb4f7c0 7
B-cell receptor pathway mutations are infrequent in patients with chronic lymphocytic leukemia on continuous ibrutinib therapy, file 170e8dcf-56e1-434f-b80b-83272230b00b 4
Characteristics and Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Receiving Ibrutinib for ≥5 Years in the RESONATE-2 Study, file 4e0da921-3996-44b9-b887-068eb5a0e2b3 3
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study, file dcac6fe3-3eb0-40fa-9242-32e9f231985a 3
Exposure to animals and increased risk of marginal zone B-cell lymphomas of the ocular adnexae, file e0c35a4b-ea68-5883-e053-d805fe0ac580 1
Totale 137
Categoria #
all - tutte 384
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 384


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/20235 0 0 0 0 0 0 0 0 0 0 4 1
2023/2024131 6 4 3 17 5 2 68 8 8 10 0 0
Totale 137